Mainz Biomed shares surge 13.24% after-hours after announcing innovative cancer detection solutions at MEDICA 2025.

Mainz Biomed surged 13.24% in after-hours trading following its announcement to showcase innovative cancer detection solutions at MEDICA 2025, as highlighted by GlobeNewswire. This event, coupled with prior positive developments such as regulatory approvals for its ColoAlert® in Switzerland and the UK, partnerships, and progress in pancreatic cancer screening trials, reinforced investor confidence in the company’s pipeline and market expansion. The immediate catalyst appears to be the MEDICA 2025 announcement, which underscores Mainz Biomed’s strategic focus on advancing non-invasive cancer diagnostics, aligning with recent regulatory and commercial milestones that collectively position the firm as a growing player in the oncology screening sector.